BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Revealing the Specialty of Food Matching: Improving Culinary Encounters - 27 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
- 3People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
- 47 Odd Apparatuses to Make Your Party Stick Out!
- 5Top 20 Style Brands for Pioneers
- Could the Star of Bethlehem have actually been a comet?
- Novo Nordisk gears up for December Ozempic launch in India, sources say
- 7 Well known Vacation spots In The US
- 5 Chiefs That Changed Our Opinion on Film
- Geminid meteor shower 2025 peaks next week. Here's what you need to know about this year's best meteor shower
- Which '80s Film Actually Holds Up Today?
- Chinese mega embassy could bring security advantages, says No 10
- Astronauts head home early after medical issue
- 'Dancing With the Stars' Season 34 finale: Who might win the mirror ball trophy? Where do the remaining contestants rank?
